Amgen IncNASDAQ:AMGN
- LAST PRICE298.6100
- TODAY'S CHANGE (%)2.2400 (0.7558%)
- Bid / Lots298.4900/ 2
- Ask / Lots298.6600/ 4
- Open / Previous Close297.1800 / 296.3700
- Day Range
- 52 Week Range
- Volume452,833
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AMGN |
|---|---|---|
| 09:32 ET | 33092 | 297.815 |
| 09:34 ET | 3478 | 297.65 |
| 09:36 ET | 6516 | 297.455 |
| 09:38 ET | 8470 | 297.49 |
| 09:39 ET | 4098 | 296.845 |
| 09:41 ET | 4085 | 296.97 |
| 09:43 ET | 2953 | 297.1501 |
| 09:45 ET | 5352 | 296.68 |
| 09:48 ET | 2689 | 296.67 |
| 09:50 ET | 1760 | 296.06 |
| 09:52 ET | 6996 | 296.318 |
| 09:54 ET | 2770 | 296.275 |
| 09:56 ET | 3093 | 296.44 |
| 09:57 ET | 1020 | 295.78 |
| 09:59 ET | 3162 | 295.73 |
| 10:01 ET | 2976 | 295.93 |
| 10:03 ET | 5992 | 295.8 |
| 10:06 ET | 4318 | 296.075 |
| 10:08 ET | 8478 | 296.56 |
| 10:10 ET | 2042 | 296.705 |
| 10:12 ET | 4656 | 296.9796 |
| 10:14 ET | 3800 | 297.18 |
| 10:15 ET | 6024 | 296.46 |
| 10:17 ET | 9130 | 296.53 |
| 10:19 ET | 4322 | 296.72 |
| 10:21 ET | 2536 | 296.86 |
| 10:24 ET | 4638 | 297.55 |
| 10:26 ET | 5612 | 297.23 |
| 10:28 ET | 2508 | 297.15 |
| 10:30 ET | 1708 | 296.69 |
| 10:32 ET | 1600 | 296.63 |
| 10:33 ET | 2619 | 296.72 |
| 10:35 ET | 2640 | 296.905 |
| 10:37 ET | 4465 | 296.98 |
| 10:39 ET | 3383 | 297.09 |
| 10:42 ET | 4051 | 297.475 |
| 10:44 ET | 2367 | 297.475 |
| 10:46 ET | 3604 | 297.4 |
| 10:48 ET | 1374 | 297.43 |
| 10:50 ET | 2266 | 297.42 |
| 10:51 ET | 1044 | 297.5099 |
| 10:53 ET | 3200 | 297.54 |
| 10:55 ET | 7278 | 297.22 |
| 10:57 ET | 3096 | 297.09 |
| 11:00 ET | 1556 | 296.94 |
| 11:02 ET | 897 | 296.93 |
| 11:04 ET | 1850 | 297.025 |
| 11:06 ET | 4471 | 297 |
| 11:08 ET | 700 | 296.88 |
| 11:09 ET | 6090 | 296.915 |
| 11:11 ET | 2081 | 297.19 |
| 11:13 ET | 1408 | 297.2 |
| 11:15 ET | 500 | 297.17 |
| 11:18 ET | 1254 | 297.19 |
| 11:20 ET | 4223 | 297.62 |
| 11:22 ET | 1768 | 297.72 |
| 11:24 ET | 3234 | 297.685 |
| 11:26 ET | 1899 | 298.005 |
| 11:27 ET | 4633 | 298.53 |
| 11:29 ET | 4388 | 298.355 |
| 11:31 ET | 3150 | 298.47 |
| 11:33 ET | 800 | 298.61 |
May 28, 2024
DJ Amgen's Rare-Disease Treatment Biosimilar Bkemv Gets FDA Approval, from 6:25PM ET on Tuesday May 28, 2024 by Dow Jones
6:25PM ET on Tuesday May 28, 2024 by Dow JonesAMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024, from 9:00AM ET on Tuesday May 28, 2024 by Dow Jones
9:00AM ET on Tuesday May 28, 2024 by Dow Jones
May 19, 2024
NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE(R) TO HELP PATIENTS LIVING WITH COPD, from 5:15PM ET on Sunday May 19, 2024 by Dow Jones
5:15PM ET on Sunday May 19, 2024 by Dow Jones
May 16, 2024
DJ Amgen Gets FDA Approval for Small-Cell Lung-Cancer Treatment, from 7:06PM ET on Thursday May 16, 2024 by Dow Jones
7:06PM ET on Thursday May 16, 2024 by Dow JonesFDA APPROVES IMDELLTRA(TM) (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER, from 6:46PM ET on Thursday May 16, 2024 by Dow Jones
6:46PM ET on Thursday May 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Amgen Inc | 159.0B | 42.7x | -0.22% |
Gilead Sciences Inc | 79.1B | 177.4x | +1.53% |
GSK plc | 92.4B | 15.9x | +6.39% |
Novartis AG | 217.2B | 22.9x | -5.59% |
Haleon PLC | 37.5B | 28.3x | --- |
Pfizer Inc | 157.6B | -459.9x | -7.10% |
Company Information
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.
Contact Information
- Headquarters
- One Amgen Center DriveTHOUSAND OAKS, CA, United States 91320
- Phone
- 805-447-1000
- Fax
- 805-447-1010
Executives
- Chairman of the Board, President, Chief Executive Officer
- Robert Bradway
- Chief Financial Officer, Executive Vice President
- Peter Griffith
- Executive Vice President, Chief Technology Officer
- David Reese
- Executive Vice President, Research and Development, and Chief Scientific Officer
- James Bradner
- Executive Vice President, General Counsel, Secretary
- Jonathan Graham
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $159.0B |
|---|---|
Revenue (TTM) | $29.5B |
Shares Outstanding | 536.4M |
Dividend Yield | 3.01% |
Annual Dividend Rate | 9.0000 USD |
Ex-Dividend Date | 05-16-24 |
Pay Date | 06-07-24 |
Beta | 0.59 |
EPS | $7.00 |
Book Value | $11.64 |
P/E Ratio | 42.7x |
Price/Sales (TTM) | 5.4 |
Price/Cash Flow (TTM) | 19.1x |
Operating Margin | 23.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
